Oral Corticosteroid-Related Healthcare Resource Utilization and Associated Costs in Patients with COPD
Tse G. et al, (2024), Advances in Therapy
QRISK3 underestimates the risk of cardiovascular events in patients with COPD.
Amegadzie JE. et al, (2024), Thorax, 79, 718 - 724
Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19.
Cass SP. et al, (2024), ERJ open research, 10, 919 - 2023
Functional MRI assessment of the lungs in fetuses that deliver very Preterm: An MRI pilot study.
Avena-Zampieri CL. et al, (2024), European journal of obstetrics, gynecology, and reproductive biology, 293, 106 - 114
Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.
Ramakrishnan S. et al, (2024), The Lancet. Respiratory medicine, 12, 67 - 77
How have we measured trial outcomes of asthma attack treatment? A systematic review.
Howell I. et al, (2024), ERJ open research, 10, 660 - 2023
Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook.
Rabe KF. et al, (2023), American journal of respiratory and critical care medicine, 208, 395 - 405
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
Bhatt SP. et al, (2023), The New England journal of medicine, 389, 205 - 214
Patients’ acceptance of outcome and experience measurements during hospitalisation for COPD exacerbations: a CICERO Clinical Research Collaboration–European Lung Foundation online patient survey
Gyselinck I. et al, (2023), ERJ Open Research, 9, 00148 - 2023
Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST)
Howell I. et al, (2023), JMIR Research Protocols, 12, e46741 - e46741
Identification of key opportunities for optimising the management of high-risk COPD patients in the UK using the CONQUEST quality standards: an observational longitudinal study.
Halpin DMG. et al, (2023), The Lancet regional health. Europe, 29
Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19
Reis G. et al, (2023), Annals of Internal Medicine, 176, 667 - 675
Temporal Release of IL-1 Family Members from Virally Infected Airway Epithelial Cells Suggests IL-36γ Is the Early Responder.
Ombredane HCJ. et al, (2023), American journal of respiratory cell and molecular biology, 68, 339 - 341
A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD.
Tse G. et al, (2023), International journal of chronic obstructive pulmonary disease, 18, 2565 - 2580
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis.
Singh D. et al, (2023), International journal of chronic obstructive pulmonary disease, 18, 1595 - 1599
Evaluation of data processing pipelines on real-world electronic health records data for the purpose of measuring patient similarity.
Pikoula M. et al, (2023), PloS one, 18
Inhaled corticosteroids for the treatment of COVID-19.
Bafadhel M. et al, (2022), European respiratory review : an official journal of the European Respiratory Society, 31
Moving the pathway goalposts: COPD as an immune-mediated inflammatory disease.
Cass SP. et al, (2022), The Lancet. Respiratory medicine, 10, 1110 - 1113